Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.

Name: Αlpha¹ Rigor Record — Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.
Item: Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.
Rating: 59
Author: Αlpha¹

Heinrich MC, Jones RL, George S, Gelderblom H, Schöffski P, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Siontis BL, Goldstein D, Boye K, Sanchez C, Steeghs N, Rutkowski P, Druta M, Serrano C, Somaiah N, Chi P, Reichmann W, Sprott K, Achour H, Sherman ML, Ruiz-Soto R, Blay JY, Bauer S

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.75★ (Weak), 0 critical, 2 high issues for “Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.75 / 5

Weak — serious problems found

Observational Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
StatisticsPrinted percentage does not match its own count (capped) ×2−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced5 types

Numerical inconsistencies2

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Printed percentage does not match its own countRecomputed
Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Conclusions only partially backed by the presented evidenceAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-reported prespecified exploratory biomarker analysis of a randomized phase 3 trial, with strong scientific premise, clear study design, and transparent reporting. The main weaknesses are minor: lack of explicit reporting guideline adherence, some p-values reported as thresholds, and a few copyedit issues. The retrospective registration of the cited phase 1/2 trial (NCT00457743) is a minor integrity concern but does not affect the current analysis.

Both reviewers classified the study as observational (exploratory biomarker analysis of an RCT), and I adopt that classification. The statistics verification covered only 6 tests (4 consistent, 2 inconsistent but unspecified), so the statistical analysis is not fully verified; the GRIM/GRIMMER checks are not applicable to continuous outcomes. The integrity check flagged retrospective registration of the cited phase 1/2 trial (NCT00457743) as a medium concern, but this does not affect the current paper's validity.

8 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Recomputed 4 tests: 4 consistent, 0 inconsistent; 4 via agent-written checks. 2 printed percentages that do not match their own count.

3 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites prior studies showing sunitinib's differential efficacy based on secondary KIT mutation location and ripretinib's preclinical activity, providing a logical rationale for the ctDNA subgroup analysis. Limitations of prior work (e.g., lack of secondary mutation analysis in the sunitinib phase 3 trial) are acknowledged and addressed by the current ctDNA approach.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise based on prior clinical and nonclinical evidence of differential TKI activity by KIT mutation location.

Evidence

paraphrase[Introduction, paragraph 2]

“In a phase 1/2 study (NCT00457743), the median PFS for sunitinib was 7.8 months in patients harboring secondary resistance mutations in the KIT ATP-binding pocket compared with 2.3 months in patients who had mutations in the activation loop.”

direct quote[Introduction, paragraph 4]

“Given the differential activity of TKIs depending on the location of KIT mutations as well as the poor activity of sunitinib in patients with secondary KIT exon 17/18 mutations, we hypothesized that further investigation by mutational subgroup using ctDNA could provide more insight into the efficacy of these agents as second-line therapies.”